{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3,"youtube":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"SUNRAY-01","nct_id":"NCT06119581","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunray-01-nct06119581. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"SUNRAY-01","arms":[{"description":"LY3537982 Dose level 1 administered orally in combination with pembrolizumab administered intravenously (IV) in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Dose Optimization: LY3537982 Dose Level 1 plus Pembrolizumab","type":"EXPERIMENTAL"},{"description":"LY3537982 Dose level 2 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Dose Optimization: LY3537982 Dose Level 2 plus Pembrolizumab","type":"EXPERIMENTAL"},{"description":"LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Safety Lead In: LY3537982 plus Pembrolizumab, Pemetrexed and Platinum","type":"EXPERIMENTAL"},{"description":"LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Part A: LY3537982 plus Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Placebo administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Part A: Placebo plus Pembrolizumab","type":"PLACEBO_COMPARATOR"},{"description":"LY3537982 administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Part B: LY3537982 plus Pembrolizumab, Pemetrexed, and Platinum","type":"EXPERIMENTAL"},{"description":"Placebo administered orally in combination with pembrolizumab, pemetrexed, and platinum (cisplatin or carboplatin) administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Part B: Placebo plus Pembrolizumab, Pemetrexed, and Platinum","type":"PLACEBO_COMPARATOR"},{"description":"LY3537982 administered orally in combination with pembrolizumab administered IV in 21-day cycles. Participants may continue to receive treatment until discontinuation criteria are met.","label":"Part C: LY3537982 plus Pembrolizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2031-01","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung","Neoplasm Metastasis"],"enrollment":{"count":1264,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"LY3537982","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"Eli Lilly and Company","official_title":"SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Dose Optimization and Safety Lead-In Part B: Number of Participants with a Treatment Emergent Adverse Event(s) (TEAE)","timeFrame":"Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)"},{"measure":"Part A and Part B: Progression-Free Survival (PFS)","timeFrame":"Randomization to first documented progression of disease or death from any cause. (Estimated as approximately 1 year)"}],"references":[{"citation":"Peters S, Hochmair M, Arbour KC, Rodriguez LP, Reck M, Leal T, R Lindsay C, Shun L, William WN, Spira AI, Sabari JK, Henning Gronberg B, Nishio M, Burns TF, Girard N, Capuzzo F, Merced A, Fasnacht N, Visseren-Grul C, Negrao MV. SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. Future Oncol. 2026 Apr;22(9):1073-1082. doi: 10.1080/14796694.2026.2651961. Epub 2026 Apr 6.","pmid":"41940628","type":"DERIVED"}],"start_date":{"date":"2023-12-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT06119581"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunray-01-nct06119581"}